Clinical, radiological and molecular characterization of intramedullary astrocytomas

[1]  Tao Jiang,et al.  The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation , 2020, Acta Neuropathologica Communications.

[2]  L. Slámová,et al.  Rare IDH1 variants are common in pediatric hemispheric diffuse astrocytomas and frequently associated with Li-Fraumeni syndrome , 2020, Acta Neuropathologica.

[3]  Robert L Schmidt,et al.  Multi-Institutional Evaluation of Inter-rater Agreement of Variant Classification Based on the 2017 AMP, ASCO and CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. , 2019, The Journal of molecular diagnostics : JMD.

[4]  C. Bettegowda,et al.  Genomic Landscape of Intramedullary Spinal Cord Gliomas , 2019, Scientific Reports.

[5]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[6]  Jennie W. Taylor,et al.  Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas , 2019, Acta Neuropathologica.

[7]  L. Lebrun,et al.  Design and Validation of a Gene-Targeted, Next-Generation Sequencing Panel for Routine Diagnosis in Gliomas , 2019, Cancers.

[8]  B. Jonker,et al.  A systematic review of outcome in intramedullary ependymoma and astrocytoma , 2019, Journal of Clinical Neuroscience.

[9]  Michael A. Paolini,et al.  Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation , 2019, Modern Pathology.

[10]  M. Wood,et al.  Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities , 2019, Diagnostic Pathology.

[11]  David T. W. Jones,et al.  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.

[12]  R. McLendon,et al.  ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis , 2019, Nature Communications.

[13]  M. Bydon,et al.  Prognostic factors and survival in low grade gliomas of the spinal cord: A population-based analysis from 2006 to 2012 , 2019, Journal of Clinical Neuroscience.

[14]  R. Zafonte,et al.  Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies , 2019, Experimental Neurology.

[15]  Jong-Hee Chang,et al.  Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System. , 2018, Neurosurgery.

[16]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[17]  Yunhui Luo,et al.  Association between IDH1/2 mutations and brain glioma grade. , 2018, Oncology letters.

[18]  Juan F. García,et al.  Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing , 2018, Journal of neuropathology and experimental neurology.

[19]  Edward F. Chang,et al.  The genetic landscape of ganglioglioma , 2018, Acta Neuropathologica Communications.

[20]  K. Hoang-Xuan,et al.  FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas , 2018, Neurology.

[21]  J. Huse,et al.  Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas , 2018, Journal of neuropathology and experimental neurology.

[22]  W. Pope,et al.  Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. , 2018, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[23]  Dominik Sturm,et al.  Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location , 2018, Neuro-oncology.

[24]  A. Mukasa,et al.  Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation. , 2017, World neurosurgery.

[25]  James X. Sun,et al.  Prognostic Factors and Treatment of Spinal Astrocytomas: A Multi-institutional Cohort Analysis , 2017, Spine.

[26]  James Suh,et al.  Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.

[27]  M. Nykter,et al.  Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas , 2017, Neuro-oncology.

[28]  Arie Perry,et al.  Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy , 2016, Neuro-oncology.

[29]  Arie Perry,et al.  Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.

[30]  K. Houkin,et al.  Clinical Factors for Prognosis and Treatment Guidance of Spinal Cord Astrocytoma , 2016, Asian spine journal.

[31]  J. Brotchi,et al.  Primary Intramedullary Tumors , 2016 .

[32]  S. Nobusawa,et al.  Genetic mutations in high grade gliomas of the adult spinal cord , 2016, Brain Tumor Pathology.

[33]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[34]  E. Benzel,et al.  Molecular and clinical prognostic factors for favorable outcome following surgical resection of adult intramedullary spinal cord astrocytomas , 2016, Clinical Neurology and Neurosurgery.

[35]  Heather L. Mulder,et al.  Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology , 2016, Acta Neuropathologica.

[36]  Arie Perry,et al.  Genetics of Glioblastomas in Rare Anatomical Locations: Spinal Cord and Optic Nerve , 2016, Brain pathology.

[37]  M. Meyerson,et al.  BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology , 2015, Acta Neuropathologica.

[38]  P. Varlet,et al.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.

[39]  H. R. Haynes,et al.  BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum , 2015, Journal of neuropathology and experimental neurology.

[40]  T. Pietsch,et al.  High frequency of H3F3AK27M mutations characterizes pediatric and adult high-grade gliomas of the spinal cord , 2015, Acta Neuropathologica.

[41]  G. Herpe,et al.  Low-grade gliomas: the challenges of imaging. , 2014, Diagnostic and interventional imaging.

[42]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Horbinski.  To BRAF or Not to BRAF: Is That Even a Question Anymore? , 2013, Journal of neuropathology and experimental neurology.

[45]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[46]  K. Aldape,et al.  Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas , 2012, Acta Neuropathologica.

[47]  A. Waldman,et al.  Conventional MRI evaluation of gliomas. , 2011, The British journal of radiology.

[48]  N. Alon,et al.  BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma , 2011, Clinical Cancer Research.

[49]  A. Friedman,et al.  Impact of Tumor Histology on Resectability and Neurological Outcome in Primary Intramedullary Spinal Cord Tumors: A Single-Center Experience With 102 Patients , 2011, Neurosurgery.

[50]  D. Na,et al.  Nonenhancing Intramedullary Astrocytomas and Other MR Imaging Features: A Retrospective Study and Systematic Review , 2010, American Journal of Neuroradiology.

[51]  T. Witham,et al.  Factors associated with progression-free survival and long-term neurological outcome after resection of intramedullary spinal cord tumors: analysis of 101 consecutive cases. , 2009, Journal of neurosurgery. Spine.

[52]  Luc Taillandier,et al.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. , 2009, Neuro-oncology.

[53]  B. Scheithauer,et al.  Prognosis and treatment of spinal cord astrocytoma. , 2009, International journal of radiation oncology, biology, physics.

[54]  E. Rushing,et al.  Spinal cord malignant astrocytomas , 2003, Cancer.

[55]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[56]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[58]  D. Balériaux,et al.  Spinal cord tumors , 1999, European Radiology.